I agree. Further to this I would guess Afamelanotide would be a pretty good treatment for COVID itself due to the vasoactive, anti-oncontic and anti-inflammatory responses it produces but Clinuvel are only a small company and seem to focus on only indications which currently have no existing treatment as COVID does. But blood clots have been caused by COVID itself and this can lead to Stroke, even in younger people so todays announcement is of particular importance I believe in becoming a treatment for this severe side-effect of COVID in the future. ALL IMO DYOR
CUV Price at posting:
$28.29 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)